HekaBio’s 1st Issuance of New Shares(English translation)

HekaBio’s 1st Issuance of New Shares

On March 20, 2018, HekaBio K.K., a Tokyo based bio-venture start-up will issue a third-party allotment of new shares.

With the mission of contributing to Japanese society’s medical and healthcare markets, HekaBio K.K. was established to specialize in the development and commercialization of innovative therapies originating from overseas.

Targeting cancer and autoimmune/inflammatory disorders, HekaBio endeavors to close the gap in access to life changing therapies for patients suffering from diseases without current solutions.

HekaBio’s veteran team leverages its experience and know-how developed at two related firms—Junicon K.K., a global medical market research-based consultancy established in Tokyo in 1992, and Vorpal Technologies K.K., a pharmaceutical and medical device CRO established in Tokyo in 2013.

Through this issue of new shares, HekaBio K.K. will continue its portfolio expansion and product development based on the company mission to address the unmet needs of patients and medical professionals in Japan.


About HekaBio K.K.

Registered: November 8, 2017

Office: Yashima Bldg. 3F, 2-7-14 Toranomon, Minato-ku, Tokyo 105-0001

Tel: +81 (3) 6205-7585 Fax: +81 (3) 6205-7586

Paid-in Capital: 180 million JPY

Chief Executive Officer: Robert E. Claar


HekaBio focuses on cancer, autoimmune/ inflammatory and central nervous system disease. The management team has extensive experience and networks, both overseas and in Japan.

With a deep understanding and respect for Japanese medical needs and business practices, HekaBio continues to grow by developing its innovation pipeline with validated programs from overseas partners. HekaBio strives to eliminate the innovation gap between Japan and rest of the world with the swift launch of therapies meeting unmet medical needs in Japan.

With integrity and tenacity, HekaBio collaborates with healthcare and business partners to creatively address the unmet medical needs of patients who are fighting rare and intractable diseases.

***

最新記事

すべて表示

コスモ・ピーアール、ヘカバイオに出資両社が戦略的パートナーシップを締結

~バイオサイエンスの新たなイノベーションについて認知度とアクセシビリティの向上を図る~ 2020年9月23日 ヘカバイオ株式会社(本社:東京都中央区、代表取締役兼CEO:クレア・ロバート、以下:ヘカバイオ)と株式会社コスモ・ピーアール(本社:東京都港区、代表取締役社長:佐藤玖美、以下:コスモ)は、コスモがヘカバイオに出資し、両社が戦略的パートナーシップを締結したことを発表します。本パートナーシップ

オフィス移転のお知らせ Office Relocation

2020年8月24日より下記へ移転いたします。 〒103-0021 東京都中央区日本橋本石町3丁目3番16号 日本橋室町ビル8階 電話番号・FAX番号 変更無し 最寄り駅: 地下鉄各線 三越前駅 A8出口 徒歩3分 Effective August 24, 2020, HekaBio will relocate to new premises as follows. Nihonbashi Muro

治験実施施設追加のお知らせ

アルファ粒子線源を用いた新たな放射線治療の治験実施施設に、東北大学病院が追加されました。 詳しくはこちらへ

ヘカバイオ株式会社

〒103-0021

東京都中央区日本橋本石町3-3-16

日本橋室町ビル8階

LI-Logo.png

© 2020 HekaBio K. K.​